Microsoft and Seattle’s Adaptive Biotechnologies are seeking 1,000 people across the country for a “virtual clinical study” designed to better understand how the human immune system responds to COVID-19. Their… Read More
— Microsoft named former GE executive Tom McGuinness corporate vice president of healthcare. At GE, McGuinness was president and CEO of GE Healthcare Imaging which offers imaging technologies, analytics and… Read More
Despite a potential vaccine, the novel coronavirus could return on a seasonal basis, much like the flu, according to Seattle-based company Adaptive Biotechnologies. That’s one of the reasons Adaptive is… Read More
Pharmaceutical giant Amgen is aiming to develop a new drug to treat and prevent COVID-19, using insights from Seattle-based Adaptive Biotechnologies’ system for sequencing the human immune system, under an… Read More
Microsoft and Seattle-based Adaptive Biotechnologies announced Friday they will work together to map the immune response to COVID-19. The goal of the partnership is to study population-wide immune responses to… Read More
Editor’s note: The GeekWire Awards are now virtual on July 23. Watch live below. Everyone wanted a piece of the Seattle tech scene in 2019, from stock market investors to… Read More
Seattle-based Adaptive Biotechnologies plans to sell up to 9.2 million shares of common stock by existing shareholders, the company said in a regulatory filing Tuesday. The biotech giant went public… Read More
From Amazon to Zillow, big successes to surprising failures, it was an extraordinary year for technology and innovation emerging from and impacting Seattle and the Pacific Northwest. That’s our consensus… Read More
Adaptive Biotechnologies‘ stock rose 6 percent to $30 per share in after-hours trading on Tuesday after the company reported higher revenues and narrower losses than expected for its third-quarter earnings.… Read More
Adaptive Biotechnologies‘ CEO and co-founder Chad Robins can attribute some of his company’s notable success — see its $300 million IPO in June and the $400 million previously raised —… Read More
Adaptive Biotechnologies signed a deal with Illumina, the largest genetic sequencing firm in the U.S., to produce kits that can read the human immune system to detect diseases at labs… Read More
As it closes in on one of the most valuable land deals in Seattle history, Alexandria Real Estate Equities is betting that biotech can thrive in a real estate market… Read More
Adaptive Biotechnologies‘ stock fell 7 percent Tuesday after the company posted larger-than-expected losses during the first quarterly earnings report since it went public in June. Earnings: Adaptive reported a net loss… Read More
Adaptive Biotechnologies is charting a massive expansion of its Seattle headquarters following the completion of a recent initial public offering. The company signed a 100,000 square-foot lease, tripling its current… Read More
Adaptive Biotechnologies had a heck of a first day as a public company. Shares of the Seattle-based biotech, which makes technology to diagnose and treat diseases by reading the immune… Read More
Follow-up: Big debut: Shares of Adaptive Biotechnologies rise 100% on first day as public company The public market is bullish on Adaptive Biotechnologies. The biotech company started trading on the… Read More
Adaptive Biotechnologies has raised the price for its initial public offering, putting itself in a position to raise more cash than any other biotech IPO this year. The Seattle-based company,… Read More
Dr. Harlan Robins, co-founder and chief scientific officer of Seattle-based Adaptive Biotechnologies, stepped down from his role as head of the computational biology program at the Fred Hutchinson Cancer Research… Read More
REDMOND — A groundbreaking system that would use artificial intelligence to diagnose several diseases from a single blood test may not be far off. The project, a collaboration between Microsoft… Read More
— The former head of Juno Therapeutics, Hans Bishop, signed on as CEO of Grail, a Bay Area biotech focused on the early detection of cancer. Bishop replaces former Grail… Read More
— Natural language processing expert Jacob Eisenstein is taking a gig as a research scientist with Google AI in Seattle. Eisenstein is an associate professor at Georgia Tech and has… Read More
Chad Robins is a Cornell grad and Wharton School MBA who was working in real estate finance a decade ago when he was approached with a business idea by his… Read More
In 2017, Microsoft struck a deal with Seattle-based Adaptive Biotechnologies to develop a blood test with the promise of diagnosing dozens of diseases at once, and as part of the… Read More
Adaptive Biotechnologies, a high-flying startup that makes technology to read the human immune system, has officially filed to go public and seeks to raise $230 million from investors. Founded in… Read More
— It’s a big day for Seattle-based F5 Networks, which just named two senior executives. Mika Yamamoto joined the firm as executive vice president and chief marketing & customer experience… Read More
Smartsheet, the Seattle-area maker of work collaboration software, appointed Anna Griffin as its first chief marketing officer. Griffin was previously CMO at IEX Group, which runs a stock exchange, and… Read More
As the CEO of Adaptive Biotechnologies, Chad Robins has shown a knack for turning really good ideas into a viable business. But even Robins admits that he makes for an… Read More
Adaptive Biotechnologies has signed a $300 million collaborative licensing agreement with Genentech to develop highly personalized cancer therapies. In addition to the up-front payment, Adaptive could receive up to $2… Read More
Every day, thousands of people cross the 520 bridge between Seattle and Bellevue, Wash. But for some of those people, the daily journey is more than just a commute: It… Read More
Seattle-based biotech company Adaptive Biotechnologies announced Friday that the FDA has cleared its clonoSEQ platform for use. It marks first time a technology based on Adaptive’s immunosequencing platform has been given the green… Read More